A randomized trial of botulinum toxin A for treatment of drooling

Abstract

The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.

Prevention of unfavourable effects of cigarette smoke on flap viability using botulinum toxin in random pattern flaps: An experimental study

“…Medically , BTX is used for the treatment of many diseases including blepharospasm, spasmodic torticollis, extremity dystonia and hemifacial spasm. In addition, it is used for the treatment of palmar and axillary hyperhidrosis caused by autonomous nervous system hyperactivity (33)(34)(35)(36). Physiologically, BTX irreversibly binds to presynaptic neurons at the neuromuscular junction and inhibits the release of acetylcholine that causes muscle relaxation (37).…”

Lesions outside the CNS in Parkinson's disease

“…13,14 Intraparotid injections of botulinum toxin can reduce the saliva production but might worsen the dysphagia. 15 …”

Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead

“…54 For patients who do not respond to anticholinergic agents or who have unacceptable side effects, some data support the use of botulinum toxin injected into the parotid and submandibular glands for patients with ALS and other conditions, such as Parkinson disease. 43,[55][56][57] Although earlier studies have raised concerns about possible side effects, including worsening of dysphagia and chewing difficulties, 58,59 no significant adverse effects were reported in more recent studies, 43 in which injections were done under electromyographic guidance.…”